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Abstract
The persistent isolation of Pseudomonas aeruginosa in the airways of non-cystic fibrosis bronchiectasis (NCFB)
patients is associated with a worsening of the symptoms, increase of exacerbations, poor quality of life and
functional impairment. The objective of this study was the analysis of the eradication rate of P. aeruginosa in the
sputum of patients with NCFB treated with inhaled colistin and the effects of the treatment in the exacerbations.
This was a prospective, cohort, study of 67 NCFB patients treated with inhaled colistin at the Hospital of A
Coruña (Spain). We recorded dyspnoea, exacerbations, lung function and sputum cultures of P. aeruginosa in the
patients. The mean age of the patients was 67.25 + 14.6 years (59.7% male). The percentages of eradication of
P. aeruginosa in sputum at 3, 6, 9 and 12 months were 61.2%, 50.7%, 43.3% and 40.3%, respectively. We observed
a significant decrease in exacerbations after 1 year of colistin treatment (1.98 + 3.62) versus the previous year
(3.40 + 4.21, p < 0.001). We conclude that treatment with inhaled colistin in patients with NCFB and P.
aeruginosa in sputum can achieve high rates of eradication even in patients with several previous positive
cultures, as well as a significant decrease of exacerbations and hospital admissions.
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Introduction
In recent years, there has been an increase in the pre-
valence of non-cystic fibrosis bronchiectasis (NCFB)1
and in the economic burden caused by its manage-
ment.2 Chronic bronchial infection (CBI) is fre-
quently associated with NCFB and characteristically
the dominant pathogens are Pseudomonas aeruginosa
and Haemophilus influenzae.3,4 Infection with P. aer-
uginosa is associated with worsening of symptoms,5
poorer health-related quality of life,6 increased
exacerbations and accelerated decline in forced
respiratory volume in the first second (FEV1).
7,8 Also,
it is one of the predictive factors of worse prognosis in
the available severity indexes.7,9
Eradication of P. aeruginosa in CBI is challen-
ging due to its ability to growth in biofilms, the fast
appearance of resistant strains, and the difficulty of
reaching adequate concentrations of antibiotics in
the bronchial space with conventional treatments in
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some cases.10–14 However, successful eradication is
usually high in young (68–93%) and adult (79%)
cystic fibrosis (CF) patients using a variety of anti-
pseudomonal regimens, with an average time of
reappearance of 8–18 months.15–19
There are few studies of the possible role of inhaled
antibiotics in the treatment of NCFB, and they are
highly heterogeneous.13,15,20–23 Two studies with
tobramycin were prospective trials with a placebo
control group, but with a reduced number of
patients.13,23 The few studies with inhaled colistin did
not exceed 30 patients each and in only one of them
systemic antibiotics had been used previously.15,21,22
Despite the limited data available, the clinical
guidelines recommend the use of inhaled antibiotics
for the treatment of early infection by P. aerugi-
nosa.24,25 In contrast to CF, for which the prescription
of simultaneous systemic and inhaled antibiotics is
recommended,6,26 for NCFB inhaled antibiotic
(tobramycin or colistin for 3–12 months) is recom-
mended only after failure of a previous eradicating
attempt with oral ciprofloxacin and/or an intravenous
(IV) cycle with two antipseudomonal antibiotics.24,25
The primary aim of this study was to evaluate the
efficacy of an antibiotic eradication protocol for
P. aeruginosa infection consisting of the administra-
tion of systemic antibiotics followed by inhaled
colistin for 12 months in a cohort of patients with
NCFB. The secondary aim was to determine whether
the use of inhaled colistin is associated with decreased
exacerbations with respect to the year prior to the
initiation of treatment.
Material and methods
This 12-month prospective study was conducted
between 1 January 2010 and 31 August 2015 at the
bronchiectasis outpatient clinic of the University Hos-
pital in A Coruña (Spain). The research protocol
described here adhered to the principles of the
Declaration of Helsinki and was approved by the
Ethics Review Board of the Hospital Universitario
A Coruña. All patients were informed orally and in
writing of the procedures, potential risks and implica-
tions of accepting this study.
This study included consecutive NCFB patients aged
18 years if they had (1) a diagnosis based on clinical
presentation and high-resolution computed tomography
(HRCT), (2) 1 cultures of P. aeruginosa but had not
previously had eradication therapy, (3) treatment with
inhaled colistin and follow-up for at least 1 year from the
start of the inhaled antibiotic, and (4) no modifications
in the base treatment for respiratory disease during the
study period including previous year.
The exclusion criteria were (1) patients with CF or
traction bronchiectasis due to pulmonary fibrosis,
(2) indication of inhaled colistin as lung transplant
prophylaxis, (3) infection with other Gram-negative
non-fermenter bacteria, (4) having started treatment
with regular nebulized antibiotics without prior IV or
oral antipseudomonal antibiotics, (5) patients that
achieved successful eradication of P. aeruginosa with
only systemic antibiotic treatment, and (6) lack of
compliance with follow-up protocol.
Patients underwent standard clinical follow-up pro-
cedures and all of them were informed about the col-
lection of data from their medical history, and gave
informed consent.
Study design
In the first assessment (inclusion visit), all patients
underwent the same diagnostic protocol as suggested
by the 2010 British Thoracic Society and Spanish
guidelines.24,25 We routinely attempt to diagnose the
aetiology of bronchiectasis following established
guidelines.24
We collected data on demographics, exposure fac-
tors, familiar genetic diseases, co-morbidities, long-
term treatments, respiratory symptoms (cough, sputum,
dyspnoea using the Medical Research Council scale),
physical exploration, microbiological findings in spu-
tum cultures in previous year, HRCT, laboratory deter-
minations including immunoglobulins (IgG, IgA, IgM,
IgE), alfa-1 antitrypsin, autoimmunity, sweat test for
chloride concentration (genetic testing in case of sus-
pected CF) and number of exacerbations in previous
year (oral cycles of antibiotics, emergency visits or
hospitalizations). Clinical, radiological and treatment
histories were obtained from the electronic health
records and from the interview to the patient. Spirome-
try was performed in all patients, including forced vital
capacity (FVC) and FEV1.
27
All patients with positive culture for P. aeruginosa
received an eradication protocol which included oral
ciprofloxacin 750 mg twice daily for 3 weeks (mild-
moderate symptoms in outpatients) or IV tobramycin
5 mg/kg plus beta-lactam antipseudomonal antibiotics
for 2 weeks (outpatients with severe symptoms, with
purulent bronchorrhea, or patients admitted for
exacerbation due to P. aeruginosa that were immedi-
ately referred for follow-up). Variations from the
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protocol occurred mainly because of drug allergy,
intolerance or insusceptibility, and in this case two
alternative IV antipseudomonal antibiotics were used
at the clinician’s discretion. In case of persistence of
P. aeruginosa in the sputum, inhaled colistin (Pro-
mixin 1 MIU twice daily) was administered with
the I-neb® Adaptive Aerosol Delivery (AAD)
device (Philips Respironics, Chichester, UK) during
a 12-month period (Figure 1). Subjects were
instructed to self-administer the treatment at home.
A short-acting bronchodilator was administered
before nebulized colistin as needed in case of cough
and/or wheezing in order to reduce adverse effects.
Monitoring of the patients followed standard clin-
ical practice in visits every 3 months. Subjects were
questioned concerning adherence to the treatment,
changes in symptoms such as cough, dyspnoea, spu-
tum production and wheezing. Blood tests (serum
chemistry, haematology) and spirometry were per-
formed in each visit. Samples of sputum were cul-
tured monthly during the first 3 months and every
2 months thereafter.
All bacteriological analyses were performed on
spontaneous sputum samples obtained before colistin
administration and tested the presence of P. aerugi-
nosa and other typical respiratory pathogens. The
Murray–Washington criteria for sputum quality were
used in all cases, with all samples having less than
10 squamous cells and more than 25 leukocytes per
low-power microscope field. All samples were
Figure 1. Chart showing participants in the study. BQ: bronchiectasis; HRCT: high-resolution computed tomography;
CF: cystic fibrosis; IV: intravenous; OR: oral.
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cultured in standard blood agar and Mc-Conkey and
Saboraud media. The microorganisms isolated were
identified by standardized or automated means, and
the antibiogram was made.
Eradication of P. aeruginosa was defined as a neg-
ative culture on all sputum samples taken at the
moment of evaluation (3, 6, 9 and 12 months since
the beginning of treatment). Inhaled colistin was
stopped only in the case of negative cultures of
P. aeruginosa for at least 12 months. CBI was defined
by the isolation of P. aeruginosa in sputum culture on
three or more occasions, at least 1 month apart.
Patients who were unable to provide sputum samples
due to the absence of a productive cough were classi-
fied as not having chronic infection for the purposes
of analysis. In case of CBI, inhaled colistin treatment
was continued indefinitely.
The number of episodes of exacerbations was
recorded for 1 year pre- and post-eradication protocol.
An exacerbation of bronchiectasis was defined as a
clinical deterioration for which oral or IV antibiotics
were prescribed in the presence of at least one (and
usually more than one) of the following symptoms:
increasing cough, increasing sputum volume, worsen-
ing sputum purulence, worsening dyspnoea, increased
fatigue/malaise, fever and haemoptysis. Exacerba-
tions were classified as ambulatory management,
emergency visits or hospital admission. Exacerba-
tions were recorded from patient histories and verified
using administrative databases. Previous exacerba-
tions were defined with the same criteria as for the
prospectively recorded exacerbations during colistin
treatment.
Statistical analysis
We initially performed a descriptive analysis of the
variables included in the study. The qualitative vari-
ables are presented as absolute values and percen-
tages. For quantitative variables, the results are
expressed as means and standard deviations, maxi-
mum and minimum values and quartiles.
Univariate comparisons between patients with or
without eradication in the 3-, 6-, 9- and 12-month
periods were tested with Pearson’s w2 or Fisher’s
exact test for categorical variables. We used the
Wilcoxon test to compare continuous variables after
analysing the normality assumption with the Kolmo-
gorov–Smirnov test. Variables selected for compari-
son between groups (eradication vs. non-eradication
at different times) were age, gender (female vs. male),
smoking status (never smoked vs. ex/active smoker),
first positive sputum cultures of P. aeruginosa, pro-
portion of patients with concomitant azithromycin
treatment, systemic antibiotics used for eradication
(oral ciprofloxacin vs. IV antipseudomonal antibio-
tics), P. aeruginosa morphotype mucoid, mean FVC
post-bronchodilatation (% predicted) and FEV1 post-
bronchodilatation (% predicted). A logistic regression
analysis was performed to determine the factors
related to the eradication of P. aeruginosa. Age and
gender were included as covariates in all models, as
well as all variables with p < 0.10 in univariate anal-
ysis (concomitant treatment with azithromycin,
P. aeruginosa mucoid) and also included variables
that showed significant influence in literature in era-
dication in CF (first positive sputum for P. aeruginosa
and systemic antibiotics). A forward stepwise strategy
was used. Statistical analysis was performed using the
SPSS software package version 20.0 (SPSS Inc.,
USA). A p value <0.05 was considered statistically
significant for all analyses.
Results
Ninety-six patients diagnosed with NCFB and pre-
senting P. aeruginosa in sputum were selected for the
eradication protocol. Eleven patients were excluded
due to the following reasons: seven patients had indi-
cation related to infection prophylaxis for lung trans-
plantation, one was diagnosed with CF during the
follow-up, three had other concomitant Gram-
negative microorganism different from P. aeruginosa
when treatment started. Of the remaining 85 patients,
13 achieved successful eradication with only systemic
antibiotic treatment, and 5 failed to comply with first
follow-up visit. The data correspond to 67 patients
with a mean age of 67.25 + 14.6 years (range
16–87 years), predominantly males (59.7%). Patient
baseline characteristics are shown in Table 1. Twenty-
five patients received 2 weeks of IV antipseudomonal
antibiotics and the remaining 42 patients received
oral ciprofloxacin.
Table 2 shows the number of positive P. aerugi-
nosa sputum cultures per patient prior to the admin-
istration of inhaled colistin. Nineteen patients (28.3%)
started treatment after two sputum cultures positive
for P. aeruginosa (one isolate prior to the systemic
antibiotic regimen and persistence in control sputum),
and in 48 patients (72%) P. aeruginosa had been iso-
lated on three or more occasions.
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The eradication of P. aeruginosa after 3 months
was observed in 41 patients (61.2%), of whom 34
patients (50.7%) continued with negative cultures
after 6 months, 29 patients (43.3%) after 9 months
and 27 patients (40.3%) after 1 year. There were eight
patients (11.9%) presenting positive cultures at month
3 of the treatment who were negative at month 6. Of
these, seven patients (10.7%) remained negative after
9 and 12 months.
We did not observe significant differences in the
eradication of P. aeruginosa in the short or long term
depending on the number of previous positive sputum
cultures (2 or 3) (Table 3). Differences in other
variables between patients with and without eradica-
tion at 3, 6, 9 and 12 months are shown in Table 4. In
the logistic regression model, the only variable asso-
ciated to the eradication rate was the presence of the
mucoid P. aeruginosa (p < 0.001).
We observed a decrease in the number of exacer-
bations after administration of inhaled colistin from
(mean + SD) 3.40 + 4.21 in the year before to 1.98
+ 3.62 the following year (p < 0.001). When the type
of exacerbations (oral antibiotic cycles, emergency
visits or hospital admissions) were analysed indepen-
dently, a significant reduction in both hospital admis-
sions (p < 0.001) and number of antibiotic cycles (p¼
0.018) was also observed, but not of emergency visits
(p¼ 0.526) (Table 5). Most patients (70%) had two or
more exacerbations in the previous year. Of the 19
patients who had the first hospital admission in the
previous year, 4 patients (21%) had at least one
admission the following year.
Table 1. Patient characteristics at the beginning of treat-
ment (n ¼ 67).
Age (years), mean + SD (range) 67.25 + 14.6
(16–87)
Sex, % males 59.7
Tobacco use, n (%)
Ex-smokers 26 (39)
Smokers 4 (6)





Immune defect 5 (7.5)
Deficit of alfa-1 antitrypsin 4 (6.0)
Rheumatoid arthritis 2 (3.0)
Ciliary dyskinesia 2 (3.0)
Yellow nail syndrome 1 (1.5)
Coinfection with other pathogens, n (%)
Staphylococcus aureus 2 (3.0)
Haemophilus influenzae 6 (10.0)
Streptococcus pneumoniae 4 (6.0)
Pseudomonas aeruginosa infection, n (%)
First-ever isolation 19 (28.3)
Previously isolated 48 (71.7)
Inhaled corticosteroids, n (%) 55 (87)
Bronchodilators, n (%) 60 (95)
Macrolides, n (%) 46 (69)
Dyspnoea MRC, n (%)
Grade 0 6 (9)
Grade 1 15 (22.4)
Grade 2 29 (43.3)
Grade 3 15 (22.4)
Grade 4 2 (3)
Dyspnoea MRC, media + SD 1.88 + 0.96











% predicted + SD
57.49 + 24.74
FEV1/FVC, ratio + SD 54.59 + 14.66







n ¼ number of patients; SD: standard deviation; COPD ¼ chronic
obstructive pulmonary disease; MRC¼ dyspnoea according to the
Medical Research Council scale; BQ ¼ bronchiectasis; HRCT ¼
high-resolution computed tomography; FVC ¼ forced vital capac-
ity; FEV1 ¼ forced expiratory volume in 1 second.
Table 2. Number of positive sputum for P. aeruginosa
(separated at least 1 month) previous to the initiation of












aAll patients had at least two positive sputum previous to the start
of the treatment with inhaled colistin because of the two previ-
ous attempts at eradication with antibiotics.
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Mild adverse effects (cough and/or wheezing) were
reported by five (7.5%) patients during the first month
of treatment but did not result in discontinuation of
therapy.
Discussion
This study shows that P. aeruginosa may be eradi-
cated in a high percentage of NCFB patients with a
treatment based on systemic antibiotics followed by
inhaled colistin even when previously they had pre-
sented several positive cultures. In addition, our study
suggests that this therapy may be effective in reducing
exacerbations. In our study, we observed eradication
rates of P. aeruginosa in NCFB patients of 61.2, 50.7,
43.3 and 40.3% after 3, 6, 9 and 12 months of treat-
ment, respectively.
There are only three published studies that analyse
the use of inhaled colistin for P. aeruginosa eradica-
tion in NCFB patients. Two studies including 18 and
19 patients found that eradication success was lower
than ours (21.4% and 16%, respectively) after an
average 41 and 21.2 months of treatment.21,22 The
possible reasons for these differences with our study
are that in these cases the patients had not received
systemic antibiotics previous to inhaled colistin, a
different colistin regimen and type of nebulizer, or
no treatment with macrolides. In our study, 69% of
the patients maintained a simultaneous treatment with
macrolides.
A prospective study with 25 patients receiving
inhaled colistin plus systemic antibiotics for 3 months
showed an eradication rate of 43% at 14.3 months, very
similar to ours at 12 months.15 Although the value of
systemic antibiotics in P. aeruginosa eradication ther-
apy in NCFB patients is still under investigation, the
results of White et al. and our study coincide in pre-
senting higher eradication rates than studies that use
inhaled antibiotic only. The use of oral/IV antibiotics
may increase the chances of eradication because
inhaled antibiotics may not reach areas of the lung due
to obstruction of the airways by mucus.
The largest study to date with inhaled colistin
included 144 patients (73 treated with colistin, 71
with placebo) and was carried out over 6 months with
a dose of 1 MIU every 12 hours.12 Although a signif-
icant decrease in the load of P. aeruginosa was
reported, the efficacy of eradication was not specified.
Two studies using only inhaled tobramycin have
shown eradication rates of 35% and 22.2% at 6 and
12 weeks, respectively.13,20 The only randomized,
placebo-controlled study using IV ceftazidime plus
tobramycin during 14 days followed by inhaled tobra-
mycin for 3 months reported an eradication rate of
54.5% after 15 months, in line with our results.23 The
success of the eradication therapy in this last case can
be due to having started after a first isolate of
P. aeruginosa from sputum in contrast with typically
after the second or more isolates. However, in our
study, we did not obtain significant differences in the
eradication rate as a function of the number of previ-
ous positive sputum with P. aeruginosa, suggesting
that eradication should be attempted both when
P. aeruginosa isolation is recent as if there is long-
term chronic infection.
Currently the optimal treatment regimen and dura-
tion has not been determined. The studies of White
and Orriols reached eradication rates similar to ours
after 3 months but in the first case the treatment also
included oral ciprofloxacin and in the second the
treatment was started after first isolation and did not
include patients with mucoid P. aeruginosa.15,23
Compared with non-mucoid P. aeruginosa, the
mucoid morphotype is associated with a lower per-
centage of success in eradication treatment.28,29 In our
study, up to 72% of the patients had more than three
P. aeruginosa-positive sputum isolations and in
59.7% of these the morphotypes were mucoid. Our
results differ from some authors that suggest that the
timing of the administration of antimicrobial therapy
may be critical, as there may be a window of
Table 3. Eradication of P. aeruginosa after 3, 6, 9 and 12





n % n %
Eradication at month 3 0.785
2 sputum, n ¼ 19 11 58 8 42
3 sputum, n ¼ 48 30 62 18 38
Eradication at month 6 0.531
2 sputum, n ¼ 19 10 53 9 47
3 sputum, n ¼ 48 24 50 24 50
Eradication at month 9 0.438
2 sputum, n ¼ 19 9 47 10 53
3 sputum, n ¼ 48 20 42 28 58
Eradication at month 12 0.319
2 sputum, n ¼ 19 9 47 10 53
3 sputum, n ¼ 48 18 38 30 62
aw2 test.
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opportunity after which antibiotic eradication treat-
ment is no longer successful. In our study, 10% of the
patients reached eradication after the third month. Our
current practice is to maintain inhaled antibiotic for
1 year after the last positive isolation.
Sodium colistimethate is usually used at a dose of
2 million IU every 12 hours dissolved in 4 ml of the
most isotonic solution possible, but with the use of the
I-neb nebulizer (Philips Respironics®) the dose can be
reduced to 1 million IU every 12 hours. The medica-
tion is released only during patient inhalation and not
continuously as in all other nebulizers.
Comparison of exacerbations between pre- and
post-treatment with inhaled colistin found a signifi-
cant reduction in the number of exacerbations during
the year with treatment. We observed significantly
reduced hospital admissions and antibiotic cycles in
the patients treated, but not of visits to the emergency
room (ER). This reflects the fact that exacerbations
that require a visit to the ER are usually severe and
result in hospital admission. There are a few small
studies that have demonstrated a significant reduction
in exacerbations in line with our study.11,14,22
Besides, in one of the most important clinical trials
of aerosolized antibiotics for patients with NCFB, a
clear trend of increase of time to first exacerbation
was demonstrated when patients with good adherence
to treatment were selected.12 Our results are consis-
tent with a recent study that showed that an important
risk factor predicting benefit from inhaled antibiotics
is a history of frequent pulmonary exacerbations.30 In
our case, 70% of the patients had >2 exacerbations in
the previous year, while 40% of the patients in the
clinical trial had no exacerbations in the previous
year. A strength of our study is that the number of
exacerbations is quite high in a large number of
patients; in contrast, several recent trials have failed
due to a low exacerbation rate in the patients.
The main limitations of our study were that it was
performed in a single centre with no placebo-controlled
group. However, our methods and management by a
Table 4. Characteristics of patients with NCFB with and without P. aeruginosa eradication in the 3, 6, 9 and 12 months
follow-up.a,b
Eradication
3 months 6 months 9 months 12 months
Yes (n ¼ 41) No (n ¼ 26) Yes (n ¼ 34) No (n ¼ 33) Yes (n ¼ 29) No (n ¼ 38) Yes (n ¼ 27) No (n ¼ 40)
Age (years) 65.9 + 14.8 69.3 + 14.0 64.5 + 15.6 70.1 + 13.0 63.7 + 16.3 69.9 + 12.6 64.4 + 16.4 69.1 + 13.1
Sex, males, n (%) 24 (58.5) 16 (61.5) 19 (55.9) 21 (63.6) 16 (55.2) 24 (63.2) 15 (55.6) 25 (62.5)
Ex/active smokers, n (%) 19 (46.3) 11 (42.3) 15 (44.1) 15 (45.5) 12 (41.4) 18 (47.4) 11 (40.7) 19 (47.5)
First P. aeruginosa culture, n (%) 11 (26.8) 8 (30.7) 10 (52.6) 9 (47.4) 9 (47.4) 10 (52.6) 9 (47.4) 10 (52.6)
Concomitant azithromycin, n (%) 27 (65.9) 19 (73.1) 23 (67.6) 23 (69.7) 18 (62.1) 28 (73.7)c 16 (59.3) 30 (75)
Oral ciprofloxacin 26 (63.4) 16 (61.5) 22 (64.7) 20 (60.6) 19 (65.5) 23 (60.5) 17 (63.0) 25 (62.5)
P. aeruginosa mucoid 18 (43.9) 22 (84.6)d 14 (41.2) 26 (78.8)c 10 (65.5) 30 (78.9)d 8 (70.4) 32 (80)d
Mean FVC post-BD, % predicted 80.4 + 21.5 78.3 + 19.2 80.2 + 23.1 79.1 + 17.9 80.3 + 20.8 79.1 + 20.4 80.1 + 21.2 79.3 + 20.2
Mean FEV1 post-BD, % predicted 58.3 + 26.3 56.1 + 22.5 57.5 + 27.1 57.4 + 22.7 57.6 + 26.7 57.3 + 23.4 56.7 + 27.4 58.1 + 23.1
NCFB: non-cystic fibrosis bronchiectasis; FVC post-BD: forced vital capacity post-bronchodilatation (% predicted); FEV1 post-BD:
forced expiratory volume in 1 second post-bronchodilatation (% predicted).
aData are presented as mean + standard deviation (X + SD).
bp Values: comparisons between groups were tested using the Pearson’s w2 (categorical variables) or Wilcoxon test (non-normally




Table 5. Number of exacerbations before and during
treatment with inhaled colistin.
n Mean + SD Difference p Valuea
Hospital admissions <0.001
Previous year 75 1.14 + 1.56 0.712
During treatment 28 0.42 + 1.33
Emergency room visits 0.526
Previous year 18 0.28 + 0.89 0.077
During treatment 23 0.35 + 1.36
Cycles of antibiotics 0.018
Previous year 128 1.94 + 2.80 0.758
During treatment 78 1.18 + 1.73
Total exacerbations <0.001
Previous year 214 3.40 + 4.21 1.381
During treatment 129 1.98 + 3.62
n ¼ number of patients; SD ¼ standard deviation.
aTest of Wilcoxon.
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single researcher assured low variability in data acqui-
sition and homogeneous management of patients and
application of clinical protocols before and after the
intervention. Other possible limitation is that, although
we verified the collection of the drug at the Pharmacy
and also evaluated self-reported adherence in a struc-
tured interview in each visit, we did not perform an
analysis of the stored adherence data in the I-neb nebu-
lizer system. However, all patients attended all follow-
up visits. Finally, another possible limitation of the
study was that the patient selection was not homoge-
nous with regard to timing of P. aeruginosa infection.
However, this fact has allowed us to observe that era-
dication is possible even in patients with several pre-
vious isolations.
We conclude that a high rate of long-term eradica-
tion of P. aeruginosa in NCFB patients can be
achieved with administration of systemic antibiotics
followed by inhaled colistin, and we recommend this
approach based on our experience with patients in real
clinical conditions. Pseudomonas eradication should
be attempted even when Pseudomonas is present in
several samples of sputum. In line with previous stud-
ies of different aerosolized antibiotics for
NCFB,11,12,14,22 our study demonstrated a notable
clinical impact of inhaled colistin, with a significant
reduction of exacerbations and an ensuing significant
decrease in hospital admissions.
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